Clinical Trial Update: Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the combination of veliparib and irinotecan hydrochloride in patients with metastatic or unresectable solid tumors, including tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor
• Triple-negative Breast Cancer
• Unresectable Solid Tumor

Drugs mentioned

• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: COMPLETED